Filing Flows › Xenetic Biosciences (XBIO) › R&D spending
Xenetic Biosciences (XBIO) R&D spending by quarter
Xenetic Biosciences' R&D spending was $552K in Q2 2026 (second quarter 2026), -17% from Q1 2026. Over the last 7 quarters it ranged from $552K (Q2 2026) to $1.0M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $552K | -17% | -16% |
| Q1 2026 | $661K | -14% | -25% |
| Q4 2025 | $773K | +2% | -26% |
| Q3 2025 | $756K | +15% | — |
| Q2 2025 | $657K | -25% | — |
| Q1 2025 | $879K | -16% | — |
| Q4 2024 | $1.0M | — | — |
Q2 2026 at a glance
Xenetic Biosciences, Q2 2026: revenue $661K (+12% year over year), operating margin -147.1%, net loss $930K, operating cash flow −$875K. The chart follows the revenue to costs, profit and cash.
Questions
What is Xenetic Biosciences' R&D spending?
Xenetic Biosciences' R&D spending was $552K in Q2 2026 (second quarter 2026), -17% from Q1 2026.
How has Xenetic Biosciences' R&D spending changed?
Over the last 7 quarters it ranged from $552K (Q2 2026) to $1.0M (Q4 2024).